NextGen Bioscience, Inc. (OTC: NXGB) is a drug development biotechnology company focused on the identification, evaluation and acquisition of drug candidates for treatment and prevention of oncological and infectious diseases in human beings. All product candidates target indications with significant unmet need and substantial market potential. Subsequent value-addition at low cost brings benefits to both patients and stakeholders. These programs will then be transferred to larger organizations, either other biotech companies and/or Big Pharma, who have the infrastructure to bring the products to market.
All acquisition candidates are underpinned by patent applications or granted patents which confer protection in the major jurisdictions worldwide.
NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has the necessary infrastructure to take the products to market. Revenues generated from licensing activities will then be reinvested in research and development by NextGen to benefit patients, partners and the Company’s investors.
NextGen is able to keep operating costs to a minimum by outsourcing all product development work to established specialist service providers and Universities to add significant value, but at low cost. NextGen’s experienced Management team and Scientific Advisory Board will guide and direct development of the products to add maximum value.
In addition, NextGen has identified a number of promising potential acquisitions of R&D projects, which can be acquired immediately at costs significantly below past investments made in them. These, and other future acquisitions, will ensure that NextGen’s pipeline of products are maintained at the forefront of scientific and medical developments, again, bringing maximum benefit to stakeholders.
The main target indication area is cancer treatment and in particular:
* Prostate cancer
* Breast cancer
* Colorectal cancer
Business Strategy
Today early stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing companies to access promising new and emerging compounds and technologies. Dealmaking in the pharmaceutical industry is constantly growing; big pharmaceutical companies are forecast to receive around 40-50% of their revenue from in-licensed products by 2010 (Pharmalicensing, 2006). The balance of dealmaking activity has also moved, from the later stages of development to the early stages, where deals have not only increased in number but value too. The average early stage deal value has risen from US$65.3 million in 2001 to US$125.1 million in 2005 (Burrill & Company, 2006).
NextGen is engaged in the development and commercial licensure of novel therapeutic proteins that disrupt the growth of cancers. Our patented drug and product portfolio includes a prostate cancer target and a breast cancer target as well as a promising acquisition pipeline. All of NextGen’s product candidates target disease indications which represent a significant unmet need, as well as having substantial potential market values.
NextGen intends to follow an outlicensing strategy, whereby programmes are outlicensed at preclinical, or Phase I, to organizations which have the necessary infrastructure to bring the products to market.
Cancer Therapeutics Market
Cancer is a devastating disease, characterised by abnormal growth and proliferation of cells which may invade adjacent tissues and spread to other areas of the body. According to the World Health Organisation (2006), cancer accounts for 13 percent of all deaths worldwide. As a result, the market for effective cancer therapeutics is immense, bringing in revenues of US$ 23.6 billion in 2004, projected to rise to US$ 60.6 billion by 2011. Even in the 21st century, cancer treatment regimes are based on chemotherapy, highly toxic regimes with significant side-effects, but new developments are emerging based on targeted therapies which are directed specifically at the cancer, without harming healthy cells. Analysts broadly predict targeted therapies, such as monoclonal antibodies to drive the total market growth by adding to existing therapies and attracting new patients.
NextGen’s proprietary anti-cancer candidates include Prostaganin (targeting prostate cancer) and Tetanolic (targeting breast cancer) which have, in preliminary studies, shown to be able to target cancer cells without affecting normal tissue and therefore have potential to be developed into blockbuster drugs. Further oncological candidates are under evaluation. Further technology platforms include an improved method for identification of the cancer stem cells which are the precursors of breast cancer – this exciting technology will aim to facilitate the identification of unique biomarkers on these precursor cells, which will then allow their specific destruction.
An emerging indication area for NextGen is in infectious disease, particularly hospital acquired infections such as MRSA. MRSA infections are becoming more prevalent in healthcare settings: in 1974, MRSA infections accounted for two percent of the total number of infections; in 1995 it was 22 percent; and in 2004 it was 63 percent (US Centers for Disease Control, 2007). The bacteria responsible are increasingly resistant to existing antibiotics. One of NextGen’s potential acquisition candidates will target hospital acquired infections such as MRSA.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.